The upcoming earnings report for Apellis Pharmaceuticals, Inc. is scheduled for Tuesday, May 5th, with a consensus estimate EPS of -0.38.
Today, Apellis Pharmaceuticals, Inc. is priced at $40.95, showing no price change. Trading volume is at $1.58 million, reflecting a 30.71% increase compared to the average.
In the latest quarterly earnings report on Monday, February 23rd, Apellis Pharmaceuticals, Inc. had a consensus estimate EPS of -0.39.
The company's cash flow indicates a net change of -$12.84 million, with operating cash flow at -$14.18 million. Cash at the end of the period stands at $467.76 million.
Apellis Pharmaceuticals, Inc. reported revenue of $199.91 million, with a gross profit of $170.19 million. The company incurred an operating income of -$51.14 million, resulting in a net income of -$58.95 million.
Key ratios reveal a gross profit margin of 85.13%, while the net profit margin stands at -29.49%. The return on equity is -15.93, and the price to book ratio is 8.55.
The balance sheet shows total assets of $1 billion, total liabilities of $705.11 million, and net debt of $18.55 million.
This real-time financial report provides a snapshot of Apellis Pharmaceuticals, Inc.'s current financial standing and performance metrics.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.